Otonomy to Report Fourth Quarter and Full Year 2015 Financial Results and Provide Corporate Update
March 09 2016 - 7:46PM
Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company
focused on the development and commercialization of innovative
therapeutics for diseases and disorders of the ear, today announced
it will report financial results for the fourth quarter and full
year 2015 as well as provide a corporate update at 4:30 p.m. ET on
March 7, 2016.
The live call may be accessed by dialing (877) 305-6769 for
domestic callers and (678) 562-4239 for international callers with
conference ID code number: 61289571. A live webcast of the call
will be available online in the investor relations section of
Otonomy’s website at www.otonomy.com and will be archived there for
30 days. A telephone replay of the call will be available by
dialing (855) 859-2056 for domestic callers or (404) 537-3406 for
international callers and entering the conference code number:
61289571.
About Otonomy
Otonomy is a biopharmaceutical company focused on the
development and commercialization of innovative therapeutics for
diseases and disorders of the ear. OTIPRIO (ciprofloxacin otic
suspension) is approved in the United States for use during
tympanostomy tube placement surgery and commercial launch is
expected in the first quarter of 2016. OTO-104 is a steroid in
development for the treatment of Ménière's disease and other severe
balance and hearing disorders. A Phase 3 trial in Ménière's disease
patients is underway in the United States with a second trial
expected to be initiated in the EU during the first quarter of
2016. OTO-311 is an NMDA receptor antagonist for the treatment of
tinnitus that is in a Phase 1 clinical safety trial. Otonomy’s
proprietary formulation technology utilizes a thermosensitive gel
and drug microparticles to enable single dose treatment by a
physician. For additional information please visit
www.otonomy.com.
Cautionary Note Regarding Forward Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or future financial or operating performance of Otonomy.
Forward-looking statements in this press release include, but are
not limited to, Otonomy's expectations regarding the timing of
commercial launch of OTIPRIO and the timing of the OTO-104 Phase 3
clinical trial for Ménière's disease in the EU. Otonomy's
expectations regarding these matters may not materialize, and
actual results in future periods are subject to risks and
uncertainties. Actual results may differ materially from those
indicated by these forward-looking statements as a result of these
risks and uncertainties, including but not limited to: Otonomy's
limited operating history and its expectation that it will incur
significant losses for the foreseeable future; Otonomy's ability to
obtain additional financing; Otonomy's dependence on the commercial
success of OTIPRIO and regulatory success and advancement of
additional product candidates, such as OTO-104 and OTO-311; the
uncertainties inherent in the clinical drug development process,
including, without limitation, Otonomy's ability to adequately
demonstrate the safety and efficacy of its product candidates, the
preclinical and clinical results for its product candidates, which
may not support further development, and challenges related to
patient enrollment in clinical trials; Otonomy's ability to obtain
regulatory approval for its product candidates; side effects or
adverse events associated with Otonomy's product candidates;
competition in the biopharmaceutical industry; Otonomy's dependence
on third parties to conduct preclinical studies and clinical
trials; Otonomy's dependence on third parties for the manufacture
of OTIPRIO and product candidates; Otonomy's dependence on a small
number of suppliers for raw materials; Otonomy's ability to protect
its intellectual property related to OTIPRIO and its product
candidates in the United States and throughout the world;
expectations regarding potential market size, opportunity and
growth; Otonomy's ability to manage operating expenses;
implementation of Otonomy's business model and strategic plans for
its business, products and technology; and other risks. Information
regarding the foregoing and additional risks may be found in the
section entitled "Risk Factors" in Otonomy's Current Report on Form
8-K filed with the Securities and Exchange Commission (the "SEC")
on January 5, 2016, and Otonomy's future reports to be filed with
the SEC. The forward-looking statements in this press release are
based on information available to Otonomy as of the date hereof.
Otonomy disclaims any obligation to update any forward-looking
statements, except as required by law.
Contacts:
Media Inquiries
Canale Communications
Heidi Chokeir, Ph.D.
Senior Vice President
619.849.5377
heidi@canalecomm.com
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jul 2023 to Jul 2024